Doctors Weigh Prescribing Controversial Alzheimer s Drug theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.
Jul 12, 2021
As physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer’s disease approved in 18 years, patients want to know: “Will this medication help me and how much?”
Doctors explaining the pros and cons of Aduhelm won’t have a definitive answer. “On an individual basis, it will be absolutely impossible to predict,” said Dr. Allan Levey, director of the Goizueta Alzheimer’s Disease Research Center at Emory University.
Cognitive decline varies widely among people who have started experiencing memory and thinking problems or who are in the earliest stage of Alzheimer’s the patients in whom Aduhelm was tested, Levey noted.
Por Judith Graham
Mientras médicos y expertos en políticas de salud debaten los méritos de Aduhelm, el primer fármaco para el Alzheimer aprobado en 18 años, los pacientes simplemente quieren saber: “¿me ayudará?”.
Alzheimer’s Greater Los Angeles is a local, dementia-focused nonprofit with five locations in Southern California. (Heidi de Marco/KHN)
Los médicos no tienen una respuesta definitiva. “En cada persona, será absolutamente imposible de predecir”, dijo el doctor Allan Levey, director del Centro de Investigación de la Enfermedad de Alzheimer Goizueta, en la Universidad Emory.
El deterioro cognitivo varía ampliamente entre las personas que han comenzado a experimentar problemas de memoria y pensamientos, o que se encuentran en la etapa más temprana del Alzheimer, los pacientes en los que se evaluó Aduhelm, apuntó Levey.
Doctors weigh benefits and risks of prescribing Alzheimer s drug Aduhelm phillyvoice.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phillyvoice.com Daily Mail and Mail on Sunday newspapers.